These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26419615)

  • 1. A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone.
    Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1321-33. PubMed ID: 26419615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study.
    Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L
    Lancet Psychiatry; 2018 Feb; 5(2):155-166. PubMed ID: 29336948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation.
    Peacock A; Degenhardt L; Hordern A; Larance B; Cama E; White N; Kihas I; Bruno R
    Int J Drug Policy; 2015 Dec; 26(12):1265-72. PubMed ID: 26123898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids.
    Peacock A; Bruno R; Cama E; Kihas I; Larance B; Lintzeris N; Hordern A; White N; Ali R; Degenhardt L
    Drug Alcohol Rev; 2015 Nov; 34(6):611-22. PubMed ID: 26084592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The characteristics of a cohort who tamper with prescribed and diverted opioid medications.
    Larance B; Lintzeris N; Bruno R; Peacock A; Cama E; Ali R; Kihas I; Hordern A; White N; Degenhardt L
    J Subst Abuse Treat; 2015 Nov; 58():51-61. PubMed ID: 26286818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients.
    Sankey C; Setnik B; Harsanyi Z; Michalko K; Yang Z; Geoffroy P
    J Opioid Manag; 2016; 12(2):149-59. PubMed ID: 27194200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?
    Raffa RB; Taylor R; Pergolizzi JV
    Expert Opin Drug Saf; 2014 Feb; 13(2):181-90. PubMed ID: 24206269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
    Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
    Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
    Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
    Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The implications of tamper-resistant formulations for opioid rotation.
    Pappagallo M; Sokolowska M
    Postgrad Med; 2012 Sep; 124(5):101-9. PubMed ID: 23095430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study.
    Peacock A; Bruno R; Larance B; Lintzeris N; Nielsen S; Ali R; Dobbins T; Degenhardt L
    Drug Alcohol Depend; 2016 Sep; 166():125-33. PubMed ID: 27430400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
    Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
    Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.
    Keast SL; Owora A; Nesser N; Farmer K
    J Manag Care Spec Pharm; 2016 Apr; 22(4):347-56. PubMed ID: 27023688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Formulation Advances in Extended-Release Medications for Pain Control.
    Jones MR; Carney MJ; Kaye RJ; Prabhakar A; Kaye AD
    Curr Pain Headache Rep; 2016 Jun; 20(6):36. PubMed ID: 27084375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamper-resistant opioid formulations in the treatment of acute pain.
    Passik SD
    Adv Ther; 2014 Mar; 31(3):264-75. PubMed ID: 24526323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.
    Vosburg SK; Jones JD; Manubay JM; Ashworth JB; Shapiro DY; Comer SD
    Addiction; 2013 Jun; 108(6):1095-106. PubMed ID: 23316699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the resistance of a geopolymer-based drug delivery system to tampering.
    Cai B; Engqvist H; Bredenberg S
    Int J Pharm; 2014 Apr; 465(1-2):169-74. PubMed ID: 24556174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.